Back to Search

DAVID LEBWOHL, MD

MD

Nephrology Physician

NPI: 1558377051Individual

Specialties, Licenses & Credentials

Internal Medicine Physician

Internal Medicine

Code: 207R00000X

40140(MA)
Nephrology PhysicianPrimary

Internal Medicine — Nephrology

Code: 207RN0300X

40140(MA)

Research & Publications (20)

Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
PMID 18446338·Cancer Chemother Pharmacol·2009
3-trial
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
PMID 18653228·Lancet·2008
3-trial
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.
PMID 18332469·J Clin Oncol·2008
3-trial
Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat).
PMID 18182676·J Clin Oncol·2008
8-other
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
PMID 17606973·J Clin Oncol·2007
3-trial
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
PMID 17606975·J Clin Oncol·2007
3-trial
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
PMID 17606972·J Clin Oncol·2007
3-trial
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
PMID 16730273·Semin Oncol·2006
6-review
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane.
PMID 16586011·Invest New Drugs·2006
3-trial
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
PMID 16172907·Cancer Chemother Pharmacol·2006
3-trial

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Request Appointment

Contact & Hours

Address
77 HERRICK ST, SUITE101
BEVERLY, MA 01915

Quick Facts

NPI
1558377051
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
2
Locations
1
Publications
20

Are you this provider?

Claim Your Profile